Stem cell preparation system close to approval in US
This article was originally published in Clinica
Executive Summary
Nexell Therapeutics' Isolex stem cell preparation system, is close to gaining FDA approval for use as an adjunct to cancer chemotherapy. The Irvine, California-based company says that it has received an approvable letter from the FDA for its Isolex 300 and automated Isolex 300i Cell Selection Systems, which are used to purify cells in bone marrow and peripheral blood transplantation.